[ET Net News Agency, 22 November 2021] CStone Pharmaceuticals (02616) said the company
(CStone) and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui) announced a strategic
partnership and exclusive licensing agreement on anti-CTLA-4 mAb CS1002 in the Greater
China region. This strategic partnership marks another milestone in CStone's mission to
introduce innovative oncology therapies in China after the commercial launch of two
first-in-class drugs this year.
CStone granted the exclusive rights to Hengrui for research, development, registration,
manufacturing and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region.
CStone will retain the rights to develop and commercialize anti-CTLA-4 mAb CS1002 outside
of Greater China. CStone and Hengrui will partner respective R&D and commercial expertise
to accelerate the development and commercialization of anti-CTLA-4 mAb CS1002, a backbone
immuno-oncology asset, to fully unleash its commercial value.
Under the terms of the agreement, CStone will be eligible for an upfront payment and
potential milestone payments up to approximately US$200 million in addition to the
double-digit royalties. Hengrui will obtain the exclusive rights for research,
development, registration, manufacturing and commercialization of anti-CTLA-4 mAb CS1002
in Greater China. CStone will retain the rights to develop and commercialize of CS1002
outside of Greater China. (RC)